aTyr Pharma, Inc.
ATYR
$0.53
-$0.03-5.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | -32.82% | -50.79% | |||
| Gross Profit | 32.82% | 50.36% | |||
| SG&A Expenses | 5.48% | -18.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.71% | -45.07% | |||
| Operating Income | 22.71% | 44.68% | |||
| Income Before Tax | 22.72% | 45.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.72% | 45.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 0.00% | -50.00% | |||
| Net Income | 22.72% | 45.76% | |||
| EBIT | 22.71% | 44.68% | |||
| EBITDA | 22.94% | 44.96% | |||
| EPS Basic | 22.74% | 46.23% | |||
| Normalized Basic EPS | 22.70% | 46.26% | |||
| EPS Diluted | 22.74% | 46.23% | |||
| Normalized Diluted EPS | 22.70% | 46.26% | |||
| Average Basic Shares Outstanding | 0.03% | 0.88% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||